tirzepatide cyprus SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of ECO 2026: tirzepatide shows potential

liver disease, mental health outcomes and functional impairment) are not directly captured beyond what is reflected through the models health-state/event utilities and disutilities, and the results should be interpreted accordingly

Tirzepatide is administered once weekly via subcutaneous injection, and whilst there is no specific time of day recommended in the prescribing information, maintaining a consistent weekly schedule is important

Results The nanogel exhibited 99.6 nm particle size, 33.0 mV zeta potential, 91.6% entrapment efficiency, and sustained GLU release (87% at 24h)

Supports reducing uneven skin tone